| 1.3506 -0.039 (-2.83%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.64 |
1-year : | 1.81 |
| Resists | First : | 1.4 |
Second : | 1.54 |
| Pivot price | 1.34  |
|||
| Supports | First : | 1.17 |
Second : | 0.98 |
| MAs | MA(5) : | 1.38 |
MA(20) : | 1.34 |
| MA(100) : | 1.39 |
MA(250) : | 1.47 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 44.8 |
D(3) : | 47.5 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 2.98 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARTL ] has closed below upper band by 45.8%. Bollinger Bands are 5.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.39 |
| Low: | 1.33 - 1.34 | 1.34 - 1.35 |
| Close: | 1.34 - 1.35 | 1.35 - 1.36 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Fri, 26 Jul 2024
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 91.5% in July - Defense World
Mon, 15 Jul 2024
Artelo Biosciences Inc (ARTL) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Mon, 15 Jul 2024
Artelo stock jumps 13% after FDA okays ART26.12 Phase 1 study (NASDAQ:ARTL) - Seeking Alpha
Tue, 02 Jul 2024
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform - StockTitan
Tue, 30 Mar 2021
Artelo Biosciences (ARTL): Drug Cannibalization By Cannabis Will Dwindle Potential Revenue - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -3.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.95 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.4 % |
| Return on Equity (ttm) | -70.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.43 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|